MyCartis is an immuno-diagnostic solution provider assuring accurate, clinical guidance with its sample to answer Evalution® platform. MyCartis develops its own immuno-diagnostic menu for the clinical user and collaborates with partners to port assays on its platform.
MyCartis primarily focuses on Serology in particular Allergy, Auto Immune and Infectious diseases. Also Oncology and Immuno-oncology are important and one of the assays in development will monitor adverse events in cancer patients undergoing immuno-oncology treatment.
In addition to the existing Evalution® RUO platform, MyCartis is developing a CE-IVD clinical configuration and has obtained its ISO13485 certification.
MyCartis was founded in 2014 integrating 2 branches of activity: the Evalution® platform which was spun out from Biocartis and selected biomarker assay “content” from Pronota.
Meet our knowledge bank
Mieke Van Acker
Hilde Windels is executive chair of the Board of Directors and co-CEO. She holds a Masters in Economics (Commercial Engineer) from the University of Leuven (Belgium) and has close to 20 years of experience in biotech with a track record of business and corporate strategy, building and structuring organizations, private fundraising, M&A and public capital markets. She worked as CFO for several biotech companies until 2011 when Hilde joined Biocartis. She started as CFO, transitioning to the co-CEO role in 2015 and CEO a.i. in 2017. She still serves as board member at Biocartis. In addition, Mrs. Hilde Windels is member of the boards of Erytech, Ablynx, MDxHealth and VIB.
Mieke Van Acker is co-CEO. She is a seasoned executive in the Life Science industry. At Merck Life Sciences Mieke Van Acker was promoted Vice President of Strategy and Business development for the Lab Solution unit after she was the VP of Sales Global Bioscience business. She started her career as a Protein application specialist in Belgium for Pharmacia (now part of GE Healthcare) before she moved to Waters and Millipore holding global responsibilities in different specialist and director roles for the life sciences business at Merck. Mieke Van Acker has a master degree in Biochemistry and Post degree in Business Administration both at the KU Leuven, Belgium. Mieke Van Acker is active in supporting Biotech Ventures and companies in the region of Ghent, Belgium.
Els Decoster is Director of the Assay Development. Els holds a PhD and Master of Science in Biotechnology from the University of Ghent. As Postdoctoral fellow, Els did cancer research at the department of Molecular Biology of the University of Ghent, Belgium. Els Decoster has a wide expertise in immunoassay, next to cell based assays and real-time PCR. She worked on projects with biotech and pharma companies involving Alzheimer, Cardio Vascular, Virology, and Oncology. Before joining MyCartis, Els was for 14 years head of molecular biology and R&D at Cerba Health Care.
Chief Scientific Officer
Wouter Laroy is the Chief Scientific Officer at MyCartis. He obtained his PhD in biotechnology from Ghent University in 1999 and has over 15 years of experience in Life Science Industry with a strong focus on technology development and R&D and with a strong record in business development, marketing and corporate and partnering strategy. In 2006, he started at Pronota where he became the Head of Operations and Technology development. Then he transitioned to Mycartis in 2014 as Vice President Scientific Marketing. From Pronota’s early days and continued at MyCartis, Wouter has been instrumental in the discovery, validation and bringing to market new diagnostic solutions to help solve unmet medical needs.
Geert Tackaert is Mycartis’ CFO. He holds a Master in Economics (Commercial Engineer) from Brussels University, a Master in Management of Vrije Universiteit Brussels and is Graduate in Fiscal Sciences from Fiscale Hogeschool Brussels. After a career with EY of 7 years as a Manager, he became Finance Director at Newtec in 2005 before he started working with MyCartis in 2015.
Bert Verbruggen is BU manager Evalution. In this capacity he manages the development teams and leads the product development activities for the Evalution multiplex platform. Bert holds a master in Bioengineering and a PhD of Bioscience Engineering, on the topic of microfluidics and bioassays. In 2014, he joined Verhaert, an innovative product development company, where he worked in various technical and leading roles. As such Bert worked for companies such as Novartis and GSK on IVD and microfluidic related products. Bert joined MyCartis in 2016, initially as System Lead.
Board of directors
representing Gengest BVBA
representing Valiance Asset Management Ltd.
representing Korys Investments NV
Mr. Rudi Mariën obtained a Master in Pharmaceutical Science at the University of Ghent and specialized in clinical biology. He was founder, shareholder and CEO of several medical laboratories, including Barc NV, a leading international central clinical lab. In addition, Mr. Mariën was cofounder, reference shareholder and president of Innogenetics. Through his management company, Gengest BVBA, Mr. Mariën currently has board mandates in different stock listed public (MDxHealth, Quest for Growth,…) and private biotech companies (Multiplicom, Myoscience, Oyster Shell, …). In addition, Rudi Mariën is chairman of the Board of the stock listed company Biocartis Group NV.
Mr. Jan Pensaert is the founder and CEO/CIO of Valiance Asset Management Ltd., a specialist investment business. From 2003 to 2007, Mr. Pensaert was CEO of La Fayette Investment Management, a leading fund of hedge funds. During his tenure, the assets under management of the La Fayette Funds increased from $750MM to $5.5B. Prior to La Fayette, Mr. Pensaert was responsible for the European-based investment management and research activities of the Permal Group. Prior to that, he was active at Lazard in Corporate Finance M&A, where he advised on transactions with a total value of more than $40B. He holds a BA in Business Economics from the University of Gent, Belgium, and a Masters in Banking & Finance from the University of Aix-Marseille.
Ms Annie Vereecken received her degree as a Pharmacist from the Catholic University of Louvain. A master in clinical pathology was obtained in 1977. She is the founder of the Labo Riatol in Antwerp, which acquired the A.M.L. laboratory in 2001. In 2007 she became CEO of the Medhold group of medical labs with further lab acquisitions, including the hospital laboratory in Lokeren, the Labo Van Waes in Bruges, the group Clinilabo and Labo Rigo in Genk.
Christoph is a Senior Investment Manager at Korys, focusing on the fund’s investments in the life science sector. In this capacity, he currently represents Korys on the board of Agendia, Bluebee, Genae, MRM Technologies and MyCartis. Prior to that, he was active in the Paris offices of Fortis Bank (now BNP Paribas) at the Corporate Finance and Capital Markets department. He then joined iPierian, a San Francisco based biotech company. Christoph holds a Master in Bioengineering and a Master in Applied Economics, both from the KU Leuven.
Chris De Jonghe
representing PMV NV
representing Hilde Windels BVBA
Mrs. Chris De Jonghe is Head of Life Sciences & Care at PMV (Participatie Maatschappij Vlaanderen). Prior to joining PMV she was Licensing Manager and subsequently Business Development Manager at VIB (Flanders’ Institute for Biotechnology). Since August 2013 she joined the Group Management Committee, responsible for daily management at PMV. She obtained a PhD in Biochemistry and a Bachelor degree in Laws at the University of Antwerp. She is member of the board of directors of Aelin Therapeutics, Confo Therapeutics, reMynd, Virovet, Biotech Fonds Vlaanderen, Vesalius Biocapital I& Ii, LSP V en Flanders’ Bio.
Hilde Windels is executive chair of the Board of Directors and CEO. She holds a Masters in Economics (Commercial Engineer) from the University of Leuven (Belgium) and has close to 20 years of experience in biotech with a track record of business and corporate strategy, building and structuring organizations, private fundraising, M&A and public capital markets. She worked as CFO for several biotech companies until 2011 when Hilde joined Biocartis. She started as CFO, transitioning to the co-CEO role in 2015 and CEO a.i. in 2017. She still serves as board member at Biocartis. In addition, Mrs. Hilde Windels is member of the boards of Erytech, Ablynx, MDxHealth and VIB.
Working @ MyCartis
We are a team of passionate people dedicated
to ultimately help patients with our solutions.
We work hard while having fun.
We foster teamwork while promoting individual ownership
and contribution. We live ‘respect’ and ‘transparency’.
The personal information of the job applicants who are not selected for the job, is deleted after 2 years.
* A reason for being, according Japanese tradition